News & Updates

Show Multimedia Only

Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer

21 Jun 2022

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.

21 Jun 2022

Ramipril shows favourable effects in hypertensive kids on maintenance haemodialysis

21 Jun 2022

In hypertensive children undergoing maintenance haemodialysis, ramipril helps improve biomarkers of endothelial dysfunction and inflammation in addition to its blood pressure (BP)-lowering benefits, a study has found.

21 Jun 2022

Semaglutide reduces long-term T2D risk in overweight/obese patients

21 Jun 2022 by

Once-weekly injection of semaglutide significantly reduced the 10-year risk of developing type 2 diabetes (T2D) among overweight or obese patients, according to a post hoc analysis of the STEP* 1 and 4 trials presented at ADA 2022.

21 Jun 2022

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients

20 Jun 2022 by

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

20 Jun 2022

Intravenous push shortens time to initiation of antibiotics in ED

20 Jun 2022 by

Administration of ampicillin/sulbactam, piperacillin/tazobactam, and ertapenem via intravenous push (IVP) results in better times to initiation of empiric, first-dose antibiotics in the emergency department, (ED) without increasing the incidence of adverse events (AEs), a study has shown.

20 Jun 2022

Vunakizumab safe, effective in moderate-to-severe plaque psoriasis

20 Jun 2022

Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.

20 Jun 2022

Active tea catechin eases radiation burns

20 Jun 2022

Epigallocatechin-3-gallate, a catechin that is most potent and abundant in tea, is a potential skin care solution in patients receiving radiotherapy, with a phase II study showing that it helps reduce the incidence and severity of radiation-induced dermatitis.

20 Jun 2022